| Item | Cat. No. | Application | Isotype | 
| Anti-FN extracellular domain B mAbs [Bifikafusp Biosimilar] (MABL-4459) | MABL-4459 | ELISA, FACS, Functional assay, in vivo binding | E, Kappa | 
| Anti-ACVR2B mAbs [Bimagrumab Biosimilar] (MABL-4460) | MABL-4460 | ELISA, FACS, Functional assay, in vivo binding | G1, Lambda | 
| Anti-SARS-CoV-2 Spike RBD mAbs [Bebtelovimab Biosimilar] (MABL-4432) | MABL-4432 | ELISA, FACS, Functional assay, in vivo binding | G1, Lambda | 
| Anti-EGFR/ERBB1/HER1 mAbs [Becotatug Biosimilar] (MABL-4433) | MABL-4433 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa | 
| Anti-NGFB (Canine) mAbs [Bedinvetmab Biosimilar] (MABL-4434) | MABL-4434 | ELISA, FACS, Functional assay, in vivo binding | G2, Lambda | 
| Anti-TFPI mAbs [Befovacimab Biosimilar] (MABL-4435) | MABL-4435 | ELISA, FACS, Functional assay, in vivo binding | G2, Lambda | 
| Anti-DPP4/ADCP2/CD26 mAbs [Begelomab Biosimilar] (MABL-4436) | MABL-4436 | ELISA, FACS, Functional assay, in vivo binding | G2b, Kappa | 
| Anti-TNFRSF17/CD269/BCMA/TNFRSF13A mAbs [Belantamab Biosimilar] (MABL-4437) | MABL-4437 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa | 
| Anti-TNFSF13B/CD257/BAFF mAbs [Belimumab Biosimilar] (MABL-4438) | MABL-4438 | ELISA, FACS, Functional assay, in vivo binding | G1, Lambda | 
| Anti-TIGIT/WUCAM/VSTM3 mAbs [Belrestotug Biosimilar] (MABL-4439) | MABL-4439 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa | 
| Anti-SARS-CoV-2 Spike RBD mAbs [Beludavimab Biosimilar] (MABL-4440) | MABL-4440 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa | 
| Anti-FGFR2/CD332 mAbs [Bemarituzumab Biosimilar] (MABL-4441) | MABL-4441 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa | 
| Anti-IL7R/CD127 mAbs [Bempikibart Biosimilar] (MABL-4442) | MABL-4442 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa | 
| Anti-PDL1/CD274 mAbs [Benmelstobart Biosimilar] (MABL-4443) | MABL-4443 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa | 
| Anti-IL5RA/CD125 mAbs [Benralizumab Biosimilar] (MABL-4444) | MABL-4444 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa | 
| Anti-AR-C124910XX mAbs [Bentracimab Biosimilar] (MABL-4445) | MABL-4445 | ELISA, FACS, Functional assay, in vivo binding | G1, Lambda | 
| Anti-TNFRSF10B/CD262/DR5/TRAILR2 mAbs [Benufutamab Biosimilar] (MABL-4446) | MABL-4446 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa | 
| Anti-MAPT mAbs [Bepranemab Biosimilar] (MABL-4447) | MABL-4447 | ELISA, FACS, Functional assay, in vivo binding | G4, Kappa | 
| Anti-KLRK1/NKG2D/CD314;ERBB2/CD340/HER2 mAbs [Azerutamig Biosimilar] (MABL-4416) | MABL-4416 | ELISA, FACS, Functional assay, in vivo binding | G1;G1, Kappa;Kappa | 
| Anti-SLAMF7/CD319 mAbs [Azintuxizumab Biosimilar] (MABL-4417) | MABL-4417 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa | 
      联系我们
Copyright © 2012-2029 西安迈博睿(Mabioway)生物科技有限公司 版权所有
地址:陕西省西安市浐灞生态区广运潭大道南段4555号长安大学科技园4号楼A单元2层
电话:15339069646 邮箱:info@mabioway.cn
